Heparin: role in protein purification and substitution with animal-component free material.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractHeparin is a highly sulfated polysaccharide which belongs to the family of glycosaminoglycans. It is involved in various important biological activities. The major biological purpose is the inhibition of the coagulation cascade to maintain the blood flow in the vasculature. These properties are employed in several therapeutic drugs. Heparin's activities are associated with its interaction to various proteins. To date, the structural heparin-protein interactions are not completely understood. This review gives a general overview of specific patterns and functional groups which are involved in the heparin-protein binding. An understanding of the heparin-protein interactions at the molecular level is not only advantageous in the therapeutic application but also in biotechnological application of heparin for downstreaming. This review focuses on the heparin affinity chromatography. Diverse recombinant proteins can be successfully purified by this method. While effective, it is disadvantageous that heparin is an animal-derived material. Animal-based components carry the risk of contamination. Therefore, they are liable to strict quality controls and the validation of effective good manufacturing practice (GMP) implementation. Hence, adequate alternatives to animal-derived components are needed. This review examines strategies to avoid these disadvantages. Thereby, alternatives for the provision of heparin such as chemical synthesized heparin, chemoenzymatic heparin, and bioengineered heparin are discussed. Moreover, the usage of other chromatographic systems mimetic the heparin effect is reviewed.
CitationAppl Microbiol Biotechnol. 2018 Oct;102(20):8647-8660. doi: 10.1007/s00253-018-9263-3. Epub 2018 Aug 9.
AffiliationHZI,Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7,38124 Braunschweig, Germany.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Purification of the human fibroblast growth factor 2 using novel animal-component free materials.
- Authors: Bolten SN, Knoll AS, Li Z, Gellermann P, Pepelanova I, Rinas U, Scheper T
- Issue date: 2020 Aug 30
- Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics.
- Authors: Masuko S, Linhardt RJ
- Issue date: 2012 Mar
- Heparin-binding peptide as a novel affinity tag for purification of recombinant proteins.
- Authors: Morris J, Jayanthi S, Langston R, Daily A, Kight A, McNabb DS, Henry R, Kumar TKS
- Issue date: 2016 Oct
- From Farm to Pharma: An Overview of Industrial Heparin Manufacturing Methods.
- Authors: van der Meer JY, Kellenbach E, van den Bos LJ
- Issue date: 2017 Jun 21
- Structural studies of the interaction of Crataeva tapia bark protein with heparin and other glycosaminoglycans.
- Authors: Zhang F, Walcott B, Zhou D, Gustchina A, Lasanajak Y, Smith DF, Ferreira RS, Correia MT, Paiva PM, Bovin NV, Wlodawer A, Oliva ML, Linhardt RJ
- Issue date: 2013 Mar 26